The US Food and Drug Administration (FDA) has green-lighted emergency use of the first at-home rapid coronavirus test that promises to expand testing options for Americans beyond the typical medical facilities and urgent care centers which have seen persistent delays in turnaround times.
FDA on Tuesday (17 November) gave emergency authorization to a 30-minute test kit from California-based Lucira Health.
The test works by swirling a self-collected sample nasal swab in a vial that is then placed in the test unit. In 30 minutes or less, the results can be read directly from the test unit's light-up display that shows whether a person is positive or negative for the SARS-CoV-2 virus.
The test is currently authorized for prescription use only. It has been okayed for home testing in people 14 and older.
The bulk of testing in the US continues to be done by health professionals and then processed at laboratories.
This news comes even as all 50 US states are experiencing "aggressive community spread", according to an internal White House report that leaked on Tuesday.
The US leads the world in coronavirus cases and deaths. The virus is blamed for more than 248,000 deaths since it entered the country on 21 January 2020.
(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 999/year is the best way you can support our efforts.